Researchers conduct metabolite analysis of ALS patient blood plasma

May 29, 2020

High-throughput analysis of blood plasma could aid in identification of diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis (ALS), according to research from North Carolina State University. The work sheds further light on a pathway involved in disease progression and appears to rule out an environmental neurotoxin as playing a role in ALS.

ALS is a progressive neurodegenerative disease that causes deterioration of nerve cells in the brain and spinal cord. Currently, treatments are hampered by lack of definitive targets, a diagnostic process that often takes over a year to complete, and insufficient and subjective methods for monitoring progression.

"Early diagnosis is important, but we are in dire need of quantitative markers for monitoring progression and the efficacy of therapeutic intervention," says Michael Bereman, associate professor of biological sciences at NC State and corresponding author of a paper describing the work. "Since disruptions in metabolism are hallmark features of ALS, we wanted to investigate metabolite markers as an avenue for biomarker discovery."

Bereman, with colleagues from NC State and Australia's Macquarie University, took blood plasma samples for 134 ALS patients and 118 healthy individuals from the Macquarie University MND Biobank. They used chip-based capillary zone electrophoresis coupled to high resolution mass spectrometry to identify and analyze blood plasma metabolites in the samples. This method quickly breaks the plasma down into its molecular components, which are then identified by their mass. The researchers developed two computer algorithms: one to separate healthy and ALS samples and the other to predict disease progression.

The most significant metabolism markers were associated with muscle activity: elevated levels of creatine, which aids muscle movement, and decreased levels of creatinine and methylhistidine, which are byproducts of muscle activity and breakdown. Creatine was 49% elevated in ALS patients, while creatinine and methylhistindine decreased by 20% and 24%, respectively. Additionally, the ratio of creatine versus creatinine increased 370% in male, and 200% in female, ALS patients.

Through machine learning, the algorithms that they created were then able to both separate healthy participants from ALS patients and predict the progression of the disease. The models produced results for both sensitivity (ability to detect disease), and specificity (ability to detect individuals without disease). The disease detection model performed at 80% sensitivity and 78% specificity, and the progression model performed at 74% sensitivity and 87% specificity.

"Creatine deficiency alone does not seem to be a problem - our results confirm that the creatine kinase pathway of cellular energy production, known to be altered in ALS, is not working as well as it should," Bereman says.

"These results are strong evidence that a panel of plasma metabolites could be used both for diagnosis and as a way to monitor disease progression," says Gilles Guillemin, professor of neurosciences at Macquarie University and co-author of the paper. "Our next steps will be to examine these markers over time within the same patient."

Another goal of the work was to look for evidence of exposure to an environmental neurotoxin, Beta Methylamino-L-Alanine (BMAA), which is found in green and blue algae blooms. BMAA has been associated with ALS since the 1950s, but few studies have attempted to detect it in human ALS patients. The researchers did not detect BMAA in the blood of either healthy or ALS patients.
-end-
The work appears in the Journal of Proteome Research, and was supported in part by the ALS Biomarker Consortium; ALS Association; ALS Finding a Cure; the Packard Association for ALS, and the Chancellor's Innovation Fund at NC State University. David Muddiman, Jacob and Betty Belin Distinguished Professor of Chemistry at NC State, is co-author.

Note to editors: An abstract follows

"Metabolite Profiling Reveals Predictive Biomarkers and the Absence of β-Methyl Amino-L-Alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis"

DOI: 10.1021/acs.jproteome.0c00216

Published: Online in the Journal of Proteome Research

Authors: Michael Bereman, Kaylie Kirkwood, Allyson Mellinger, David Muddiman, North Carolina State University; Gilles Guillemin, Tharani Sabaretnam, Sarah Furlong, Dominic Rowe, Macquarie University, NSW, Australia

Abstract:

By employing chip-based capillary zone electrophoresis coupled to high resolution mass spectrometry, we profiled the plasma metabolome of 134 patients diagnosed with sporadic amyotrophic lateral sclerosis (81 males and 53 females) and 118 individuals deemed healthy (49 males and 69 females). The most significant markers (p?0.01) were creatine, which was 49% elevated, and creatinine and methylhistidine which were decreased by 20% and 24%, respectively, in ALS patients. The ratio of creatine versus creatinine increased 370% and 200% for male and female ALS patients, respectively. In addition, male ALS patients on average had 5-13% lower amounts of 7 essential amino acids while females did not significantly differ from healthy controls. We developed two models using the metabolite abundances: 1) A classification model for the separation of ALS and healthy samples; and 2) A classification model for the prediction of disease progression based on the ALS functional rating score. Utilizing a Monte Carlo cross-validation approach, a linear discriminant analysis model achieved a mean area under the receiver operating characteristic curve (AUC) of 0.85 (0.06) with a mean sensitivity of 80% (9%) and specificity of 78% (10%), for the separation of ALS and controls, respectively. A support vector machine classifier predicted progression categories with an AUC of 0.90 (0.06) with a mean sensitivity 73% (10%) and specificity 86% (5%). Lastly, using a previously reported assay with a stable isotope labeled (13C315N2) spike-in standard, we were unable to detect the exogenous neurotoxic metabolite, β-methylamino-L-alanine (BMAA), in the free or protein bound fraction of any of the 252 plasma samples.

North Carolina State University

Related Amyotrophic Lateral Sclerosis Articles from Brightsurf:

Converting lateral scanning into axial focusing to speed up 3D microscopy
In optical microscopy, high-speed volumetric imaging is limited by either the slow axial scanning rate or aberrations introduced by the z-scanning mechanism.

Ammonium triggers formation of lateral roots
Despite the importance of changes in root architecture to exploit local nutrient patches, mechanisms integrating external nutrient signals into the root developmental program remain poorly understood.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Adjustable lordotic expandable vs static lateral lumbar interbody fusion devices
The objective of this study is to compare the clinical and radiographic outcomes between patients treated with static and expandable interbody spacers with adjustable lordosis for MIS LLIF.

Chirality-assisted lateral momentum transfer for bidirectional enantioselective separation
Chiral nanoparticles which twist the light were theoretically predicted to experience lateral forces perpendicular to light vector but lacks experimental verification.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

Researchers delay onset of amyotrophic lateral sclerosis (ALS) in laboratory models
Scientists have delayed the onset of amyotrophic lateral sclerosis (ALS) in laboratory models, leaving them cautiously optimistic that the result, combined with other clinical advances, points to a potential treatment for ALS in humans.

Emerging role of adenosine in brain disorders and amyotrophic lateral sclerosis
The role of adenosine in neurodegeneration and neuroregeneration has led to growing attention on adenosine receptors as potential drug targets in a range of brain disorders, including neuroregenerative therapy and treatment for amyotrophyic lateral sclerosis (ALS).

New clues about the origins of familial forms of Amyotrophic lateral sclerosis
A Brazilian study made important progress in understanding the accumulation of one of the proteins involved in amyotrophic lateral sclerosis (ALS).

Recrutement of a lateral root developmental pathway into root nodule formation of legumes
Peas and other legumes develop spherical or cylindrical structures -- called nodules -- in their roots to establish a mutually beneficial relationship with bacteria that convert atmospheric nitrogen into a useable nutrient for the legume plant.

Read More: Amyotrophic Lateral Sclerosis News and Amyotrophic Lateral Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.